The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | The addition of elotuzumab to backbone treatment regimens for myeloma: key takeaways
Bruno Costa, MD, Icahn School of Medicine at Mount Sinai, New York, NY, discusses the use of elotuzumab, a monoclonal antibody targeting SLAMF7, for treating relapsed/refractory (R/R) multiple myeloma (MM). Dr Costa conducted a meta-analysis of over 2,700 patients, which showed that the addition of elotuzumab to backbone treatment regimens improves progression-free survival (PFS), overall survival (OS), and response rates. However, elotuzumab does not benefit newly diagnosed patients, highlighting its role in later treatment lines. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
